From Podium To Practice – Breast Cancer ESMO Part 10
After progression on first-line endocrine therapy plus CDK4/6 inhibition, treatment decisions become increasingly complex in HR-positive, HER2-negative metastatic breast cancer. In this discussion, Drs. Erica Mayer and colleagues review the evERA trial, examining dual targeting with the oral SERD giredestrant combined with everolimus and how it compares with established endocrine-based regimens. The conversation highlights efficacy across broad patient populations, safety and tolerability findings, and what these results may mean for second-line treatment selection in clinical practice.